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Objectives. To assess the outcome of arterial allografts in patients receiving organ transplantation.
Design. From October 1997 to June 2005, we used fresh arterial allografts as vascular conduits in 21 patients for the treat-
ment of claudications (10), abdominal aortic aneurysm (6), complicated renal transplantation (2), acute lower extremity
ischemia (2) and gangrene (1). At the time of the vascular procedure, ten of the patients (Group A) had already undergone
organ transplantation. The mean follow up period was 32 months for renal and 37 months for heart recipients, respectively.
In 11 patients (Group B), the vascular reconstruction was undertaken simultaneously with the renal transplantation. The
mean follow up period was 49 months.
Results. There was no arterial allograft related deaths. No signs of arterial graft infection or requirement for secondary
intervention (angioplasty and/or thrombolysis) were observed during the follow up period.
Conclusions. Our experience suggests that it is possible to use fresh arterial allografts in the treatment of arterial occlusive
disease or abdominal aortic aneurysm, both in already transplanted patients and simultaneously with organ transplanta-
tion, with good results.
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Progress in transplantmedicine during the last 15 years
has led to an expanded range of eligibility criteria for
patients with an end stage organ failure selected for
an organ transplant. Potential recipients of transplanted
organs are increasingly older, with higher number of
comorbidities. Many of these patients have peripheral
arterial disease or abdominal aortic aneurysm. Further-
more, progress in transplant medicine has led to high
long-term survival rates of organ recipients. In many
of these patients, chronic immunosuppressive therapy
accelerates the process of arteriosclerosis resulting in
more marked manifestation of abdominal aortic aneu-
rysms and peripheral arterial diseases. Prosthetic vas-
cular grafts are not the most suitable material for
vascular reconstructions in this group of patients,
because of their higher susceptibility to infection.
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used for reconstructions in vascular patients, as there
were not that many other options at that time.1 They
were soon abandoned by surgeons because of their
unsatisfactory long-term patency rates and, particu-
larly, as prosthetic grafts became available.2 The
main reason for early arterial allograft occlusions
was the patient’s immune system response to alloan-
tigens, followed by graft rupture or thrombosis. No
immunosuppressive therapy was used during that
early period of vascular surgery. The interest in arte-
rial allografts was renewed when they were found to
offer good solutions in the treatment of prosthetic
graft infections.3e5
The combination of physiological properties of
fresh arterial allografts and higher risk of infection
in the field of chronic immunosuppression suggests
that these grafts should preferably be used as vascular
conduits in transplanted patients. The present report
summarizes our experience with the use of fresh arte-
rial allografts in the treatment of abdominal aortic
aneurysm (AAA) and peripheral arterial disease in
patients with previously or simultaneously trans-
planted organs.rved.
550 I. Matia et al.Material and Methods
The studywas approvedbyour local ethical committee.
Patient population
From October 1997 to June 2005, we used fresh arterial
allografts as vascular conduits in 21 patients. At the
time of the vascular procedure, ten patients, compris-
ing 6 females and 4 males (Group A), the mean age of
whomwas 59.4 years (range 50 to 67 years) had already
undergone organ transplantation. The function of all
transplanted organs (kidney e 3 patients, kidneyþ
pancreas e 1 patient, heart e 6 patients) was normal
at the time of the vascular operation. The mean time
elapsed between the organ and the arterial transplanta-
tions was 43 months (range 1 week to 108 months) in
patients with renal transplants and 49 months (range
14 to 99 months) in patients with heart transplants, re-
spectively. The mean follow up period was 32 months
(range 17 to 51 months) in renal and 37 months (range
8 to 53 months) in heart recipients, respectively.
In 11 patients, comprising 6 males and 5 females
(Group B), the mean age of whom was 52 years (range
32 to 66 years), the vascular reconstruction was under-
taken simultaneously with the renal transplantation.
The mean follow up period was 49 months (range 1 to
92 months). Two patients in this group had a previous
history of unsuccessful renal transplantation with con-
secutive graftectomy (13 and 11 years ago, 9 years ago).
Indications for vascular surgery in the group of
previously transplanted patients included claudica-
tions (6 cases), acute thrombosis of the popliteal artery
(1 case), acute lower extremity ischemia (1 case), gan-
grene of the lower extremity (1 case), and symptom-
atic mycotic abdominal aneurysm (1 case). The types
of vascular reconstructions used in this group of
patients are summarized in Table 1.
Indications for vascular surgery in the group of
patients with simultaneous renal transplantation in-
cluded asymptomatic abdominal aneurysm (5 cases),
claudications (4 cases) and vascular complications of
kidney transplantation (2 cases). The types of vascular
reconstructions and indications for the simultaneous re-
nal transplantations are summarized in Table 2. An ilio-
femoral bypass during kidney re-transplantation
because of a previously diagnosed asymptomatic illiac
occlusion was performed on one young female patient
with a history of 2 previous unsuccessful renal trans-
plantations and consecutive graftectomies. The artery
of the renal graft was anastomosed to an arterial graft.
In another case, the patient with a history of an unsuc-
cessful renal transplantation developed an acute intimalEur J Vasc Endovasc Surg Vol 32, November 2006dissection of iliac artery during renal re-transplantation
This casewas treated by iliac artery resection and substi-
tution by an iliofemoral graft. The renal graft arterywas
anastomosed to the arterial graft.
Harvest and preservation of arterial grafts
All arterial grafts were obtained from donors with the
diagnosis of cerebral death in the course of a multior-
gan harvest. The mean age of the donors (5 males, 5
females) in the group of previously transplanted
patients was 31.5 years (range 20 to 45 years). The
mean age of donors (11 males) in the group of patients
with the simultaneous arterial and renal transplanta-
tions was 30.5 years (range 15 to 44 years). Renal
and arterial grafts obtained from one donor were
both used in a single recipient.
After removal, the arterial grafts were flushed with
heparinised conservation solutions commonly used in
multiorgan harvests: custodiol (n¼ 11), UW (n¼ 6),
EuroCollins (n¼ 3) and Soltran (n¼ 1). The grafts
were stored at a temperature of about 4 degrees Cen-
tigrade using the same types of solutions as those
used for flushing, with no additional antibiotics. The
mean cold ischemic time of arterial grafts was 15.6
hours (range 5 to 21 hours) in the group of patients
with the previous organ transplantation. The mean
cold ischemic time in the group of patients with
simultaneous renal transplantation was 11.2 hours
(range 5 to 24 hours) for arterial and 13 hours (range
7 to 26) for renal grafts, respectively.
The types of arterial allografts obtained by themulti-
organ harvest and used as conduits for vascular recon-
structions in both groups of patients are summarized in
Table 3.
Immunosuppressive therapy
All patients with a history of a previous organ trans-
plantation were chronically immunosuppressed at
the time of the arterial allograft reconstruction. Immu-
nosuppressive protocols and blood levels of immuno-
suppressant drugs depended on the type of the
transplanted organ and the period elapsed between
the previous organ transplantation and the vascular
reconstruction. The immunosuppressive regimens in
patients with the renal and arterial transplantations
conducted simultaneously did not differ from those
used after a simple renal transplantation at our de-
partment. The type of immunosupressive regimens
and mean levels of cyclosporine or tacrolimus 6, 12
and 24 months after the arterial allograft reconstruc-
tions are summarized in Tables 4, 5 and 6.
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553Fresh Arterial Grafts as Conduits for Vascular ReconstructionsIn one patient, whose external iliac artery was re-
sected and substituted by an iliofemoral graft simulta-
neously with the renal transplantation, primary renal
allograft dysfunction developed and acute graftectomy
was necessary. The immunosupressive regimenwas re-
stricted tomonotherapy consisting of administering cy-
closporine A for one year. The mean blood level of
cyclosporine was 104.3 ng/ml. In one patient, renal
transplant failure occurred 62months from the simulta-
neous aortobifemoral bypass and renal transplanta-
tion. A second renal transplantation was performed 9
months later. The patient received cyclosporine A
only, the mean level of which was 74.2 ng/ml, during
this period.
The patients who have undergone an organ trans-
plantation and arterial allograft reconstructions are
carefully monitored by vascular surgeons, nephrolo-
gists and cardiologists during the follow up period.
The patency of the reconstructions is verified by clinical
examinations, ultrasonography and/or angiography
(conventional or computed), periodically (Fig. 1). The
function of the transplanted organs (heart, kidney, pan-
creas) and levels of immunosupresive drugs are moni-
tored in accordancewith our Institute’s standardpolicy
stipulating the level of care to be extended to organ
recipients.
Results
There was no death after arterial allograft reconstruc-
tions in the group of previously transplanted patients
during the perioperative and early postoperative
Table 3. Types of arterial allografts used for vascular reconstruc-
tions in 21 patients
Group A Group B
Thoracic aorta 1 4
Aortobiliofemoral graft 2 2
Aortoiliac graft 0 1
Iliofemoral graft 7 4
Group A e Patients with previously transplanted organs. Group
B e Patients with simultaneous renal transplantation
Table 4. Mean levels of cyclosporine A and types of immunosup-
pressive protocols in heart recipients 6 months, 12 months, and 24
months after arterial allograft reconstructions
6 months 12 months 24 months
Mean levels of cyclosporine A
CyA levels (ng/ml) 328,5 192,2 222,0
Immunosuppressive protocols
CyAþAzaþ Ster 3 2 1
CyAþMMFþ Ster 2 2 1
CyAþ Ster 1 1 2
CyAþAza 1 1 1
CyA e cyclosporine A, Aza e azathioprime, MMF e mycophenol
mofetil.period. Four patients (40%) died during the follow
up period. Three of them (2 heart recipients, 1 kidney
recipient) died of a carcinoma at a different anatomi-
cal location 37, 26 and 8 months after the arterial allo-
graft reconstruction and 37, 40 and 108 months after
the organ transplantation, respectively. One heart re-
cipient died a sudden death 53 months after the arte-
rial allograft reconstruction and 67 months after heart
transplantation, respectively. There was no arterial al-
lograft related death in the group of previously trans-
planted patients.
One patient (9%) in Group B died of a GIT hemor-
rhage during the early postoperative period. Two pa-
tients (18.2%) died 32 and 27 months after the arterial
allograft reconstruction and the renal transplantation
of a GIT hemorrhage and an intracerebral hemorrhage,
respectively. There were no arterial allograft related
deaths in the groupofpreviously transplantedpatients.
There was only one early surgical complication in
Group A. One renal recipient suffered from persistent
lower extremity ischaemia, despite an acute alloarte-
rial iliobiprofundal bypass (bifurcated graft with
Table 5. Mean levels of cyclosporine A/tacrolimus (FK 506) and
types of immunosuppressive protocols in renal recipients 6
months, 12 months, and 24 months after arterial allograft
reconstructions
6 months 12 months 24 months
Mean levels of cyclosporine A/tacrolimus
CyA levels (ng/ml) 260,6 265,5 122,0
FK 506 levels (ng/ml) 8,1 10,8 -*
Immunosuppressive protocols
CyAþAzaþ Ster 1 1 1
FK 506þMMF 1 1 -*
MMFþ Ster 1 1 -*
CyAþMMF 1 1 1
CyA e cyclosporine A, Aza e azathioprime, MMF e mycophenol
mofetil, FK 506 e tacrolimus.
* Follow up period shorter than 24 months.
Table 6. Mean levels of cyclosporine A/tacrolimus (FK 506) and
types of immunosuppressive protocols in patients with simulta-
neous arterial allograft reconstruction and kidney transplantation
6 months, 12 months, and 24 months after operating procedure
6 months 12 months 24 months
Mean levels of cyclosporine A/tacrolimus
CyA levels (ng/ml) 261,0 204,7 142,2
FK 506 levels (ng/ml) 7,8 9,7 6,0
Immunosuppressive protocols
CyAþAzathþ Ster 4 4 3
FK 506þMMFþ Ster 1 1 0
CyAþMMFþ Ster 2 2 1
RAPAþ FK506þ Ster 1 1 1
FK 506þMMF 1 1 2
CyAþMMF 0 0 2
CyA* 1 1 0
* In one patient an acute graftectomy was done during early post-
operative period, because of a primar renal allograft afunction. The
immunosupressive regiment was restricted to monotherapy of
cyclosporine A for one year.Eur J Vasc Endovasc Surg Vol 32, November 2006
554 I. Matia et al.proximal anastomosis on the left common iliac
artery), one week after a kidney transplantation. An
acute fresh arterial graft e posterior tibial artery by-
pass with a fresh venous allograft was performed suc-
cessfully five days after the first vascular intervention.
The patient did not have an amputation during the
follow up period. The patient died 37 months after
the operation of a carcinoma, as described previously.
In the other renal recipient, a crural and later femoral
amputation was necessary because of an impairment
of ischaemic lesion 4 months after a patent arterial
ilioprofundal cross-over bypass.
No signs of fresh arterial allograft infection, stenosis
or dilatation of implanted allografts, and no increased
risk for previously transplanted kidney grafts has
been proven in this group of patients. One renal graft
failed as a result of hypovolemic shock of the patient
bleeding from a urinary bladder carcinoma 37 months
after the renal transplantation and subsequent iliobi-
profundal bypass.
In Group B, a higher incidence of early surgical
complications was observed. Acute lower extremity
ischemia developed in one patient after an aortofe-
moral bypass and simultaneous patch angioplasty of
the contralateral deep femoral artery. Ten days after
the first intervention, an acute prosthetic proximal
femoropopliteal bypass was performed with good
results. A complete wound dehiscence treated by
Fig. 1. CT angiography one year after simultaneous abdom-
inal aortic aneurysm resection and kidney transplantation.
Donors thoracic aorta was used for substitution of resected
abdominal aorta. The graft of cadaveric kidney with 2 renal
arteries was anastomosed to the left iliac vessels.Eur J Vasc Endovasc Surg Vol 32, November 2006re-suturing occurred in another patient after an intra-
peritoneal renal transplantation and simultaneous
AAA resection and substitution with thoracic aorta
during the early postoperative period. Ischemic colitis
and perforation of the colon developed in another pa-
tient after a simultaneous AAA repair and renal trans-
plantation in the early postoperative period. The
inferior mesenteric artery was ligated during the
AAA resection. Reoperation and subtotal colectomy
was undertaken. Subsequently, acute renal failure
with a short-term need for dialysis developed. Corti-
coresistant acute rejection was diagnosed and success-
fuly treated. No signs of arterial allograft infection
were noticed in this patient during the subsequent
follow up period.
In Group B, no signs of fresh arterial allograft infec-
tion, stenosis or dilatation of implanted allografts
have been demonstrated. Ureteral stenosis of the
transplanted kidney was observed in two renal recip-
ients in the first 6 months after the operation. They
were successfully treated by short-term percutaneous
drainage nephrostomy. One primary renal allograft
dysfunction with consequent graftectomy and one
chronic renal failure 62 months from the surgery,
was noticed in the group of simultaneously trans-
planted patients.
Discussion
Advancements in transplant medicine, which are
attributable mainly to the development of new potent
immunosupressive drugs, have led to an expanded
range of eligibility criteria in selecting patients with
end stage organ failure for an organ transplant, and im-
proved posttransplantation survival rates. The number
of potential recipients of organs with co-morbities, in-
cluding serious forms of atherosclerosis, peripheral
arterial disease, abdominal aortic aneurysms and dia-
betes mellitus is growing. Severe arteriosclerosis and/
or peripheral arterial occlusive disease results in diffi-
cult arterial anastomosis and intraoperative arterial
injuries during kidney and/or pancreas transplanta-
tions.6 The number of reports describing the develope-
ment of abdominal aortic aneurysm (AAA) after renal,7
cardiac,8 pulmonary9 or liver10 transplantation is
growing.11
The choice of conduit for vascular reconstructions
in patients receiving chronic immunosuppression is
controversial. The use of prosthetic prostheses is lim-
ited by the risk of infection. The interruption of immu-
nosuppressive drugs might result in a failure of the
transplanted organ, despite the successful treatment
of the prosthetic graft infection. The risk of infectious
complications is higher, especially if a two-stage
555Fresh Arterial Grafts as Conduits for Vascular Reconstructionsprocedure is used, i.e. when the organ transplantation
follows after the vascular reconstruction.12
Since 1950, backed by experimental studies,13 fresh
arterial allografts were used as the initial material for
vascular reconstructions in humans.1,14,15 Their use,
however,was soon abandoned because of late degener-
ative changes in grafts2 and a number of previously
transplanted allografts were removed and replaced
withDacrongrafts.2 The immunogenicity of the arterial
wall was considered to be the main reason for the de-
generative changes of allografts. The immune response
against antigens in the arterial wall has been confirmed
in animals16e19 as well as in humans20,21 in the last 20
years.Allograft rejection is preventedby calcineurin in-
hibitors, such as cyclosporine A and tacrolimus.16,22e24
Arterial allografts re-appeared in clinical practice in
the 1980s and 1990s. At that time, vascular surgeons
had to cope with infections of prosthetic grafts.3e5,25e27
A good resistance of arterial allografts to infection was
themain reasonwhy theyhave been used to treat vascu-
lar prosthesis infections with good results.28e31
All the data about the abovementioned properties of
arterial allografts prompted their use in chronically im-
munosuppressed transplanted patients. In 1994 Dinis
daGama32 reported 16ABO-compatible cryopreserved
arterial allografts being transplanted into thirteen pa-
tients with a transplanted kidney who received azathi-
oprine, cyclosporine and prednisone. No signs of
cellular mediated rejection were noted in this study.
The lower immunogenicity of cryopreserved, com-
pared to fresh allografts is controversial.33e36 The most
advantageous attribute of cryopreserved grafts stored
in tissue banks is the ability to obtain suitable grafts
whenever needed. At our Institute, the Vascular Unit
is integrated into theTransplantCentre, so thishandicap
can beminimized or even completely eliminated (in the
case of simultaneous renal and arterial transplantations,
when bothgrafts are obtained from the samedonor).We
use so called fresh arterial allograftse arteries obtained
in a multiorgan harvest and stored in a preservation
solution at 4 C for a maximum of 36 hours e for two
main indications. They are used as conduits for recon-
structive surgery in the treatment of an intercurrent ob-
structive or aneurysmal vascular disease in previously
as well as in simultaneously transplanted patients.
The most frequent intercurrent vascular diagnosis
of renal recipients in Group B was asymptomatic
abdominal aortic aneurysm. There are two treatment
options to choose from in such circumstances e an en-
dovascular graft implantation, or an AAA resection
and substitution.
We utilize open surgery when there are contraindi-
cations to endovascular stents. The most frequently
recommended tactic is a two-stage procedure. Thefirst step is the abdominal aortic aneurysm resection
and substitution with a vascular prosthesis. The renal
transplantation follows later. The recommended inter-
val between the vascular reconstruction and the
subsequent renal transplantation is 6 weeks to 3
months.37,38 A simultaneous AAA resection and sub-
stitution combined with a renal transplantation is an
alternative approach in such cases. The first case of
a patient treated in this way was described by Cerilli
et al. in 1977.39 The most notable advantage of the
single-stage procedure is the necessity for only one
admission, anesthetic and operation. The cost benefit
of the one-step approach is not negligible as well.
An artificial vascular prosthesis or a fresh arterial allo-
graft are available as conduits for vascular reconstruc-
tions. The benefit of the one-stage procedure used on
a patient with an AAA combined with a renal and
liver failure has been previously documented.10
The combined arterial allograft reconstructions and
kidney transplantation is performed on an urgent ba-
sis and before the results of HLA donor’s and recipi-
ent’s antigen match testing are available. The risk of
delayed function of the renal graft is increased only
in the event of intraoperative complications.40
Arterial allografts are also used in pancreas and re-
nal transplantation when required.6,32,41 Two patients
with a history of a renal transplantation and graftec-
tomy were earmarked for renal re-transplantations in
our group. In both of them, iliofemoral allografts
were transplanted simultaneously because of the recip-
ient’s iliac artery occlussion and acute intimal dissec-
tion, respectively. The renal grafts arteries were
anastomosed to the arterial grafts.
A patient with a transplanted organ, who is under-
going immunosuppressive therapy, is an ideal recipient
for arterial allografts, if arterial reconstructive surgery is
required. On the basis of our experience, is it possible to
use fresh arterial allografts in the treatment of arterial
occlusive disease or AAA, both for patients who have
already undergone transplantation and simultaneously
with the organ transplantation, with good results.
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